Paul Wright

Paul Wright serves as the Vice President of CMC at Imugene Limited, where activities include directing comprehensive CMC initiatives for the CF33 oncolytic virus and B-cell vaccine programs in a remote capacity. Prior to this role, Paul accumulated extensive experience at Pfizer over a 21-year tenure, culminating in the position of Director of Bioprocess and Analytical within Oncology Research & Development. In this capacity, leadership of a 14-member team was essential for managing virus and protein-based projects from discovery to first-in-human trials. Other key roles at Pfizer included Associate Research Fellow and Senior Principal Scientist, where Paul led teams in the development of vaccine candidates encompassing various technologies. Earlier experience includes a role as Process Development Scientist at Cantab Pharmaceuticals.